Filing Details
- Accession Number:
- 0001628280-23-003759
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-15 17:13:39
- Reporting Period:
- 2023-02-13
- Accepted Time:
- 2023-02-15 17:13:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1501697 | X4 Pharmaceuticals Inc | XFOR | Biological Products, (No Disgnostic Substances) (2836) | 273181608 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1830901 | Arthur Taveras | C/O X4 Pharmaceuticals Inc. 61 North Beacon Street 4Th Floor Boston MA 02134 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-02-13 | 928 | $0.93 | 103,179 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
- The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.92 to $0.98, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Of the shares of common stock reported, 99,679 shares represent restricted stock units.